|Bid||0.5800 x 1300|
|Ask||0.5860 x 1100|
|Day's range||0.5801 - 0.6084|
|52-week range||0.3900 - 3.3800|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||N/A|
|Earnings date||10 Feb 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||7.00|
TORONTO, May 17, 2022--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (Cybin or the Company), a biopharmaceutical company focused on progressing "Psychedelics to TherapeuticsTM" is pleased to announce that it will participate in the morning trading bell ceremony on May 18, 2022 at the New York Stock Exchange ("NYSE") in New York City.
TORONTO, May 11, 2022--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) ("Cybin" or the "Company"), a biopharmaceutical company focused on progressing "Psychedelics to TherapeuticsTM" is pleased to announce that Doug Drysdale, Cybin’s Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright Global Investment Hybrid Conference being held at the Fontainebleau Miami Beach May 23-26, 2022.
LOS ANGELES & TORONTO, May 09, 2022--Cybin and Kernel Announce Results from Kernel Flow® Piloting of Feasibility Study Measuring Ketamine’s Effects on the Brain